Dr. Berardi completed his Hematopathology and Transfusion Medicine training in Ottawa and is now a staff Hematopathologist at the Ottawa Hospital. He holds a PhD in Biochemistry & Molecular Biology from the University of Calgary.
This presentation will focus on the changing landscape of molecular diagnostic testing for hematolymphoid neoplasms. Emphasis will be placed on best practices for interpreting molecular diagnostic tests and ways to communicate these results to optimize patient care.
At the end of the sessions, participants will be able to:
Explain the principles of molecular diagnostic testing as applies to complex malignant hematology and recommend specimen requirements needed for accurate results.
Differentiate between clinically actionable mutations and predictive markers and describe how these can influence clinical decision-making in routine practice.
Discuss myeloid neoplasms arising in the setting of germline predisposition and adopting a strategy to managing these complex cases.
Outline a general approach to laboratory management and quality assurance as it pertains to molecular diagnostics.
Target Audience: Residents
CanMEDS Roles: Medical Expert (the integrating role), Communicator, Collaborator, Leader, Health Advocate, Scholar, Professional